Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

DT2216 in Combination With Irinotecan for Children, Adolescents and Young Adults With Relapsed or Refractory Solid Tumors: A Phase I Study With Phase II Feasibility Cohort for Fibrolamellar Carcinoma

NCT06620302 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT06620302
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06620302 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
DT2216 in Combination With Irinotecan for Children, Adolescents and Young Adults With Relapsed or Refractory Solid Tumors: A Phase I Study With Phase II Feasibility Cohort for Fibrolamellar Carcinoma
Lead sponsor
Children's Oncology Group
Phase
Phase 1/2
Overall status
Suspended
Start date
June 12, 2025
Completion date
December 30, 2031
Enrollment
81 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

childhood fibrolamellar carcinoma, recurrent childhood fibrolamellar carcinoma, recurrent childhood malignant solid neoplasm, recurrent fibrolamellar carcinoma, recurrent malignant solid neoplasm, refractory childhood fibrolamellar carcinoma, refractory childhood malignant solid neoplasm, refractory fibrolamellar carcinoma, refractory malignant solid neoplasm